Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Orphanet	Ensembl
	HGNC	UniGene	Nucleotide	OMIM		UCSC

Home Page

FLASH GENE

Symbol

EPHA2

contributors: mct/pgu - updated : 09-06-2020

HGNC name	EPH receptor A2
HGNC id	3386

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

CPP1

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function tumoral     --over   associated with angiogenesis in ovarian cancer tumoral     --over   in many cancer types, including breast, ovarian, prostate, pancreatic, and lung cancer tumoral     --over   predicts poor prognosis in endometrial cancer constitutional     --over   in lung injury, contributes to vascular leak in the injured lung, and is regulated in endothelial cells by endothelin tumoral     --other   absence of EPHA2 in normal bone, and de novo expression in osteosarcomas tumoral     --over   of EPHA2 and EFNA1 plays an important role in the progression of gastric adenocarcinoma constitutional germinal mutation       lead to disorganized lens cells that subsequently contribute to altered refractive index and cataracts

Susceptibility

to cortical cataract, age-related

Variant & Polymorphism SNP	rs6678616 was the most frequent in cortical cataract, age-related

Candidate gene	could be useful for cancer diagnosis, particularly because EPHA2 appears to be overexpressed starting from early stages of cancer
	EPHA2 targeted therapy reduces angiogenesis and tumor growth in endometrial cancer uterine cancer models and should be considered for future clinical trials
	EPHA2 could be a promising candidate as a therapeutic target for Small-cell lung cancer (SCLC)
Marker	EFNA1 and EPHA2 may be useful serum markers for the detection of hepatocellular carcinoma development and progression, respectively
Therapy target
	System Type Disorder Pubmed cancer     peptides of the YSA/SWL series could be used in cancer (breast, ovarian, prostate, pancreatic, and lung) therapeutic strategies to target EPHA2, a receptor widely expressed not only in cancer cells but also in the tumor vasculature cancer     activation of EPHA2 signaling represents a possible new avenue for anti-cancer therapies that exploit the remarkable ability of this receptor to counteract multiple oncogenic signaling pathways cancer digestive colon as a potential therapeutic target in metastatic colorectal cancer cancer     therapeutic strategy that aims at the stabilization of EPHA2 dimers may be beneficial for the treatment of cancers linked to EPHA2 overexpression

ANIMAL & CELL MODELS

mice Epha2-null, Efna5-null, or both receptor and ligand (Epha2/Efna5-null) consistently develop mostly transparent lenses with an internal refractive disturbance and a grossly disturbed cellular architecture